KRT20 and diffuse large B-cell lymphoma: To better evaluate the effect of the combination, HSC NSG mice bearing an aggressive human DLBCL cell line (WSU-DLCL2) were treated with a suboptimal dose of CD20-TCB (0.15 mg/kg).